Early worsening of diabetic retinopathy with insulin and incretin-based therapies is not a consequence of rapid glucose lowering but an insulin-linked angiogenic and inflammatory phenomenon—mislabeling it as a glycemic effect risks therapeutic inertia and undermines long-term retinal protection.